Impact of Non-Fixed Versus 6 Month Fixed Retreatment Schedules on Serum Immunoglobulins Following Rituximab in Patients with Rheumatoid Arthritis
|Inmaculada de la Torre1,2, Maria J Leandro2, Delia Gerona1, Lara Valor1, Luis Carreno1 and Geraldine Cambridge2*|
|1Hospital Gregorio Marañon, Rheumatology Division, Madrid, Spain|
|2Division of Rheumatology, Department of Medicine, University College London, London, UK|
|Corresponding Author :||Geraldine Cambridge
Division of Rheumatology
Department of Medicine, University College London
E-mail: [email protected]
|Received December 04, 2012; Accepted January 17, 2013; Published January 24, 2013|
|Citation: de la Torre I, Leandro MJ, Gerona D, Valor L, Carreno L, et al. (2013) Impact of Non-Fixed Versus 6 Month Fixed Retreatment Schedules on Serum Immunoglobulins Following Rituximab in Patients with Rheumatoid Arthritis. J Clin Cell Immunol S6:005. doi:10.4172/2155-9899.S6-005|
|Copyright: © 2013 de la Torre I, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.|
|Related article at
Pubmed Scholar Google
Objectives: To assess the incidence of secondary hypogammaglobulinemia in patients with rheumatoid arthritis (RA) following multiple cycles of rituximab (RTX) related to two different therapy regimens.
Methods: 73 patients with RA were retreated using 6 months-fixed strategy and 63 patients using a non-fixed regimen. All received ≥ 2 courses of RTX. Data on serum immunoglobulins (Ig), serious infections and DAS28 were collected, with maximum follow-up being 24 months for the 6 months fixed group and 156 months for the non-fixed group). Statistics for non-parametric analysis were applied.
Results: The percentages of patients developing low IgG or IgM did not differ between groups after the 3rd cycle, but those with non-fixed retreatment tended to be higher. After 4 cycles, median IgM levels were significantly lower in both groups compared with pretreatment (p<0.05). Only patients in the fixed retreatment group receiving 4 cycles of treatment showed a significant drop in median IgG level (p<0.05). IgA levels remained within the normal range. Withdrawals due to infections per 100 patient years (py)s in patients with low IgG were higher after 3 Cycles in patients within the fixed retreatment group (4.60/100py vs 1.36/100py, CI: 0.59, 6.23). DAS28 did not differ between cohorts after multiple cycles.
Conclusions: Although the percentage of RA patients developing low IgG tended to be higher in the nonfixed group, median IgG level was significantly lower after 4 Cycles of RTX in the fixed regimen group. The fixed retreatment group also had more patients discontinuing rituximab over a shorter period of time (24 months compared with 156 months), with no significant differences in median DAS28 after multiple Cycles. If multiple cycles of RTX are to be instituted, non-fixed regime may allow the opportunity to control the disease with a lower incidence of withdrawal due to low Igs and infections.